Literature DB >> 17077361

Re: Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis.

Elena Tamborini, Tiziana Negri, Francesca Miselli, M Stefania Lagonigro, Sabrina Pricl, Silvana Pilotti.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17077361     DOI: 10.1093/jnci/djj417

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  5 in total

1.  A V530I Mutation in c-KIT Exon 10 Is Associated to Imatinib Response in Extraabdominal Aggressive Fibromatosis.

Authors:  Jean-Emmanuel Kurtz; Irène Asmane; Anne-Claire Voegeli; Agnès Neuville; Armelle Dufresne; Valère Litique; Christine Chevreau; Jean-Pierre Bergerat
Journal:  Sarcoma       Date:  2010-03-17

Review 2.  Targeted therapies: the rare cancer paradigm.

Authors:  Marco A Pierotti; Tiziana Negri; Elena Tamborini; Federica Perrone; Sabrina Pricl; Silvana Pilotti
Journal:  Mol Oncol       Date:  2009-10-28       Impact factor: 6.603

3.  Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis.

Authors:  A Dufresne; F Bertucci; N Penel; A Le Cesne; B Bui; M Tubiana-Hulin; I Ray-Coquard; D Cupissol; C Chevreau; D Perol; A Goncalves; M Jimenez; P P Bringuier; J Y Blay
Journal:  Br J Cancer       Date:  2010-07-27       Impact factor: 7.640

4.  Molecular and functional characterization of a new 3' end KIT juxtamembrane deletion in a duodenal GIST treated with neoadjuvant Imatinib.

Authors:  Vittorio Perfetti; Erik Laurini; Suzana Aulić; Maurizio Fermeglia; Roberta Riboni; Marco Lucioni; Elena Dallera; Sara Delfanti; Luigi Pugliese; Francesco Saverio Latteri; Andrea Pietrabissa; Sabrina Pricl
Journal:  Oncotarget       Date:  2017-07-18

5.  AKT1 and BRAF mutations in pediatric aggressive fibromatosis.

Authors:  Cristina Meazza; Antonino Belfiore; Adele Busico; Giulio Settanni; Nicholas Paielli; Luca Cesana; Andrea Ferrari; Stefano Chiaravalli; Maura Massimino; Alessandro Gronchi; Chiara Colombo; Silvana Pilotti; Federica Perrone
Journal:  Cancer Med       Date:  2016-04-08       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.